This inventor holds 4 USPTO granted patents and 1 published patent application and 4 EPO patents. Top assignee: Centessa Pharmaceuticals (UK) Limited. Active years: 2025-2026.
Company Filing History:
Years Active: 2025-2026
Title: James Michael Tomlinson: Innovator in Alpha1-Antitrypsin Deficiency Treatment
Introduction
James Michael Tomlinson is a notable inventor based in Babraham, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of alpha1-antitrypsin deficiency. With a total of 4 patents to his name, Tomlinson's work is paving the way for innovative therapies.
Latest Patents
Tomlinson's latest patents focus on compounds and their use for the treatment of alpha1-antitrypsin deficiency. The first patent relates to specified oxazole compounds, which are pharmaceutical compositions that may act as inducers of α-antitrypsin (A1AT). These compounds are intended for use in treating diseases or disorders such as α-antitrypsin deficiency (A1AD or AATD). The second patent involves specified benzamide compounds, which also serve as inducers of α-antitrypsin and are aimed at the same medical conditions.
Career Highlights
Tomlinson is currently associated with Centessa Pharmaceuticals (UK) Limited, where he continues to develop innovative solutions for healthcare challenges. His expertise in pharmaceutical chemistry has been instrumental in advancing treatments for serious health conditions.
Collaborations
Some of his notable coworkers include Nigel Ramsden and David John Fox, who contribute to the collaborative efforts in research and development at Centessa Pharmaceuticals.
Conclusion
James Michael Tomlinson is a prominent figure in the pharmaceutical industry, with a focus on addressing alpha1-antitrypsin deficiency through innovative compounds. His contributions are vital for the advancement of effective treatments in this area.